Table 3.

Univariate analysis of variables and effect on outcomes at 1 year in ≥20% steatosis

Recipient	Graft survival		Mortality
	HR (95% CI)	p	HR (95% CI)	p
Age	1.00 (0.99–1.01)	0.69	1.01 (1.00–1.02)	0.05
BMI	1.01 (0.99–1.02)	0.27	1.01 (0.99–1.03)	0.77
MELD	1.02 (1.01–1.03)	<0.001	1.03 (1.02–1.04)	<0.001
Etiology of LT
Noncholestatic liver disease	Ref		ref
Acute liver failure	1.62 (0.99–2.33)	0.06	1.68 (1.06–2.67)	0.03
Cholestatic liver disease	0.87 (0.63–1.22)	0.42	0.87 (0.56–1.21)	0.32
Malignant neoplasm	0.86 (0.67–1.10)	0.24	0.85 (0.64–1.13)	0.26
Other	1.36 (0.99–1.87)	0.06	1.2 (0.822–1.76)	0.34
Vent support at LT	3.01 (2.19–4.13)	<0.001	3.04 (2.12–4.36)	<0.001
Donor
Age	1.01 (1.0–1.02)	0.006	1.01 (1.00 –1.01)	0.1
BMI	1.0 (0.99–1.01)	0.85	1.00 (0.99–1.01)	0.95
Gender—female	0.95 (0.8–1.11)	0.5	0.92 (0.76–1.1)	0.35
Race
Caucasian	Ref		ref
Hispanic	1.17 (0.94–1.47)	0.17	1.11 (0.85–1.43)	0.44
AA	0.97 (0.75–1.25)	0.8	0.89 (0.66–1.2)	0.44
Asian	1.1 (0.67–1.82)	0.7	1.14 (0.66–2.0)	0.64
Other	1.31 (0.75–2.27)	0.34	1.27 (0.68–2.39)	0.45
HCV Ab+	0.69 (0.45–1.06)	0.09	0.73 (0.46–1.18)	0.2
HBV NAT+	0.0 (0.0–0.0)	0.96	0.0 (0.0–0.0)	0.97
Heavy alcohol use	1.02 (0.85–1.23)	0.85	1.02 (0.83–1.26)	0.85
Hypertension	1.24 (1.05–1.46)	0.001	1.09 (0.91–1.31)	0.35
Diabetes	1.13 (0.93–1.38)	0.21	1.03 (0.82–1.3)	0.78
DCD	1.09 (0.63–1.89)	0.75	0.98 (0.51–1.89)	0.94
CIT	1.04 (1.02–1.07)	0.0003	1.03 (1.01–1.06)	0.02
COD
Anoxia	ref		ref
CVA	1.83 (1.49–2.25)	<0.001	1.88 (1.48–2.39)	<0.001
Head trauma	1.38 (1.08–1.77)	0.011	1.54 (1.16–2.04)	0.003
CNS tumor	1.55 (0.57–4.18)	0.39	1.56 (0.5–4.94)	0.45
Unknown	1.36 (0.69–2.67)	0.38	1.83 (0.92–3.63)	0.084
DRI	1.18 (1.03–1.35)	0.018	1.16 (0.99–1.35)	0.07

AA, African American; Ab, antibody; BMI, body mass index; CIT, cold ischemic time; CVA, cerebrovascular accident; DCD, deceased after cardiac death; DRI, donor risk index; HBV, hepatitis B virus; HCV, hepatitis C virus; LT, liver transplantation; MELD, model for end-stage liver disease; NAT, nucleic acid amplification